STLN news

Latest 1 stories · newest Nov 5, 2026

STLN

Starling Reports Q3 2026 Results and Full-Year 2026 Guidance

Starling Oncology reported Q3 2026 revenue of $169.8 million and positive Adjusted EBITDA of $3.4 million, reaffirming its 2026 revenue guidance between $650M and $660M. The positive financial performance signals continued operational momentum for the value-based oncology group.

Earnings Nov 5, 2026 sentiment +0.50 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same STLN feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/STLN/newsSTART FREE